New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; clotrimazole 10 mg/g - combination - 150mg & 10mg/g - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water active: clotrimazole 10 mg/g excipient: benzyl alcohol cetostearyl alcohol cetyl palmitate octyldodecanol polysorbate 60 purified water sorbitan stearate - vaginal candidiasis. cream can be used for relief of external itching/irritation and the management of candida vulvovaginitis or infection of the peri-anal area.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water - canesoral fluconazole capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - myHealthbox

bayer ag - imidacloprid - suspension concentrate - imidacloprid 600 g/litre; methanol (phenylmethoxy) <> - insecticide - seedgrowth

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - gadobutrol 604.72mg equivalent to 1 mmol/ml - solution for injection - 1 mmol/ml - active: gadobutrol 604.72mg equivalent to 1 mmol/ml excipient: calcobutrol hydrochloric acid trometamol water for injection - gadovist 1.0 is indicated in adults and children of all ages including full-term newborns for: · contrast enhancement in cranial and spinal magnetic resonance imaging (mri). for spinal mri this includes: differentiation of intra- and extramedullary tumours, demonstration of solid tumour areas in known syrinx, determination of intramedullary tumour spread. gadovist 1.0 is especially suited for high dose indications, such as cases where the exclusion or demonstration of additional foci may influence the therapy or patient management, for detection of very small lesions and for visualisation of lesions that do not readily take up contrast media. gadovist 1.0 is also indicated for perfusion studies such as the diagnosis of stroke, the detection of focal cerebral ischaemia and tumour perfusion. · contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system. · contrast enhancement in magnetic resonance angiography (ce mra). · contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement.

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - tebuconazole - suspension concentrate - tebuconazole 430 g/litre - fungicide - fungicide

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 2000 [iu] (recombinant factor viii) - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 3000 [iu] (recombinant factor viii) - injection with diluent - 3000 iu - active: octocog alfa 3000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.